2024
AI-driven Patient-Selection For Preoperative Portal Vein Embolization For Patients With Colorectal Cancer Liver Metastases
Kuhn T, Engelhardt W, Kahl V, Alkukhun A, Gross M, Iseke S, Onofrey J, Covey A, Camacho Vasquez J, Kawaguchi Y, Hasegawa K, Odisio B, Vauthey J, Antoch G, Chapiro J, Madoff D. AI-driven Patient-Selection For Preoperative Portal Vein Embolization For Patients With Colorectal Cancer Liver Metastases. Journal Of Vascular And Interventional Radiology 2024 PMID: 39638087, DOI: 10.1016/j.jvir.2024.11.025.Peer-Reviewed Original ResearchTotal liver volumeMetastatic colorectal cancer patientsPreoperative portal vein embolizationColorectal cancer liver metastasesPortal vein embolizationCancer liver metastasesMulticenter retrospective studyColorectal cancer patientsStudent's t-testBoard-certified radiologistsVein embolizationConsecutive patientsLiver metastasesLiver volumePatient selectionRetrospective studyCancer patientsRadiomic featuresInclusion criteriaPatientsSemi-automatic segmentationLab valuesT-testSDAUCOutcomes of repeat conventional transarterial chemoembolization in patients with liver metastases
Ghabili K, Windham-Herman A, Konstantinidis M, Murali N, Borde T, Adam L, Laage-Gaupp F, Lin M, Chapiro J, Georgiades C, Nezami N. Outcomes of repeat conventional transarterial chemoembolization in patients with liver metastases. Annals Of Hepatology 2024, 29: 101529. PMID: 39033928, PMCID: PMC11558520, DOI: 10.1016/j.aohep.2024.101529.Peer-Reviewed Original ResearchConventional transarterial chemoembolizationLiver metastasesNeuroendocrine tumorsColorectal carcinomaTransarterial chemoembolizationOverall survivalLung cancerAssociated with improved patient survivalManagement of liver metastasesMetastatic liver lesionsSingle-institution analysisNonresponding patientsSurvival outcomesPatient survivalResponse assessmentTarget lesionsMetastasisLiver lesionsPatientsResponse rateChemoembolizationSurvivalLiverLesionsCancerAtezolizumab and bevacizumab in combination with TACE for patients with BCLC B HCC.
Stein S, Cheng W, Wiess C, Pollak J, Perez Lozada J, Chapiro J, Madoff D. Atezolizumab and bevacizumab in combination with TACE for patients with BCLC B HCC. Journal Of Clinical Oncology 2024, 42: tps584-tps584. DOI: 10.1200/jco.2024.42.3_suppl.tps584.Peer-Reviewed Original ResearchRates of grade 3Grade 3Child-Pugh A cirrhosisBCLC-B HCCCombination of atezolizumabCurative intent therapyMain portal veinRisk of bleedingDiagnosis of HCCSignificant autoimmune diseaseSingle arm pilot studyB HCCECOG PSEffective regimenOpen-labelOverall survivalGastroesophageal varicesIntent therapyPredicted probabilityAutoimmune diseasesHepatic arteryPortal veinHepatic encephalopathyPatientsImprove outcomes
2022
Intraarterial Therapies for the Management of Hepatocellular Carcinoma
Garg T, Shrigiriwar A, Habibollahi P, Cristescu M, Liddell RP, Chapiro J, Inglis P, Camacho JC, Nezami N. Intraarterial Therapies for the Management of Hepatocellular Carcinoma. Cancers 2022, 14: 3351. PMID: 35884412, PMCID: PMC9322128, DOI: 10.3390/cancers14143351.Peer-Reviewed Original ResearchDrug-eluting bead transarterial chemoembolizationHepatic artery infusionHepatocellular carcinomaTransarterial therapiesTransarterial chemoembolizationImage-guided locoregional therapiesBead transarterial chemoembolizationCatheter-based treatmentManagement of patientsLocoregional therapyBland embolizationIntraarterial therapyRadioembolization therapyEmbolic agentTherapyChemoembolizationCarcinomaEmbolizationPatientsArteryReviewInfusionTumorsResponse assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization
Adam LC, Savic LJ, Chapiro J, Letzen B, Lin M, Georgiades C, Hong KK, Nezami N. Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization. Clinical Imaging 2022, 89: 112-119. PMID: 35777239, PMCID: PMC9470015, DOI: 10.1016/j.clinimag.2022.06.013.Peer-Reviewed Original ResearchConceptsConventional transarterial chemoembolizationLipiodol depositionHepatic metastasesResponse assessment methodsPartial responseTransarterial chemoembolizationResponse assessmentTumor primaryStratification of responseRare primary tumorResponse Evaluation CriteriaRetrospective bicentric studyAssessment of responseQuantitative European AssociationLiver metastasesMajor complicationsBicentric studyPrimary tumorRare tumorEarly surrogateTreatment responseCT scanPatientsRECISTSolid tumorsOptimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022, 304: 228-237. PMID: 35412368, PMCID: PMC9270683, DOI: 10.1148/radiol.212426.Peer-Reviewed Original ResearchConceptsMedian overall survivalAdvanced-stage hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaBCLC BBCLC COverall survivalTumor burdenBarcelona Clinic Liver Cancer (BCLC) staging systemLiver Cancer staging systemCancer (AJCC) staging systemConventional transarterial chemoembolizationDrug-eluting beadsAllocation of patientsContrast-enhanced MRIBackground PatientsSurvival benefitRetrospective studyStaging systemC tumorsTumor volumePatientsHeterogeneous patientsMonthsChemoembolization
2021
Role of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma
Rexha I, Laage-Gaupp F, Chapiro J, Miszczuk MA, van Breugel JMM, Lin M, Konstantinidis M, Duran R, Gebauer B, Georgiades C, Hong K, Nezami N. Role of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma. Scientific Reports 2021, 11: 9337. PMID: 33927226, PMCID: PMC8085245, DOI: 10.1038/s41598-021-88426-x.Peer-Reviewed Original ResearchConceptsTotal tumor volumeConventional transarterial chemoembolizationTumor diameterIntrahepatic cholangiocarcinomaOverall survivalTumor areaICC patientsTumor volumeHigh tumor burden groupTumor analysisOS of patientsHazard ratioTransarterial chemoembolizationTumor burdenBurden groupConventional chemoembolizationHTB groupRetrospective analysisPatientsSurvival curvesMultivariate analysisChemoembolizationCholangiocarcinomaETVBaseline images
2020
Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer
Miszczuk MA, Chapiro J, Geschwind JH, Thakur V, Nezami N, Laage-Gaupp F, Kulon M, van Breugel JMM, Fereydooni A, Lin M, Savic LJ, Tegel B, Wahlin T, Funai E, Schlachter T. Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer. Translational Oncology 2020, 13: 100742. PMID: 32092672, PMCID: PMC7036424, DOI: 10.1016/j.tranon.2020.01.003.Peer-Reviewed Original Research
2019
Comparing HCC arterial tumour vascularisation on baseline imaging and after lipiodol cTACE: how do estimations of enhancing tumour volumes differ on contrast-enhanced MR and CT?
Luedemann WM, Geisel D, Gebauer B, Schnapauff D, Chapiro J, Wieners G, Steffen I, Kahn J. Comparing HCC arterial tumour vascularisation on baseline imaging and after lipiodol cTACE: how do estimations of enhancing tumour volumes differ on contrast-enhanced MR and CT? European Radiology 2019, 30: 1601-1608. PMID: 31811428, DOI: 10.1007/s00330-019-06430-2.Peer-Reviewed Original ResearchConceptsLipiodol depositionNative CT scansTumor volumeTumour vascularisationTechnical successHCC patientsCE-CTCT scanDifferent imaging modalitiesImaging modalitiesContrast-enhanced CTContrast-enhanced MRPearson correlation coefficientBaseline imagingSubgroup analysisRespective regression coefficientsCT groupLinear regression analysisCE-MRICE-MRVascularisationCTContrast phasesPatientsCTACEFluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors
Schobert I, Chapiro J, Pucar D, Saperstein L, Savic LJ. Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors. PET Clinics 2019, 14: 437-445. PMID: 31472741, DOI: 10.1016/j.cpet.2019.06.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, HepatocellularChemoembolization, TherapeuticFemaleFluorodeoxyglucose F18HumansInfusions, Intra-ArterialLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedMonitoring, PhysiologicMultimodal ImagingNeoplasm MetastasisPositron-Emission TomographyRadiopharmaceuticalsSensitivity and SpecificitySurvival AnalysisTomography, X-Ray ComputedTreatment OutcomeTumor MicroenvironmentConceptsTransarterial chemoembolizationLiver tumorsFluorine-18 fluorodeoxyglucose PETEfficacy of embolotherapyCross-sectional imaging techniquesMetastatic liver tumorsCancer cell glycolysisLocal recurrenceFluorodeoxyglucose PETTumor necrosisLiver cancerMorphologic changesCell glycolysisEmbolotherapyTumorsMonitoring responseIndividual molecular characteristicsMolecular characteristicsImaging techniquesChemoembolizationResponsePatientsRecurrencePETTherapyImmunotherapy and the Interventional Oncologist: Challenges and Opportunities—A Society of Interventional Oncology White Paper
Erinjeri JP, Fine GC, Adema GJ, Ahmed M, Chapiro J, den Brok M, Duran R, Hunt SJ, Johnson DT, Ricke J, Sze DY, Toskich BB, Wood BJ, Woodrum D, Goldberg SN. Immunotherapy and the Interventional Oncologist: Challenges and Opportunities—A Society of Interventional Oncology White Paper. Radiology 2019, 292: 25-34. PMID: 31012818, PMCID: PMC6604797, DOI: 10.1148/radiol.2019182326.Peer-Reviewed Original ResearchConceptsInterventional oncologyCancer management planCancer-related problemsInterventional oncologistsTreatment of cancerCancer patientsImmuno-oncologyInvasive proceduresInterventional radiologyRadiation oncologyOncologyImage guidanceCancerCancer researchSubspecialty fieldsPivotal roleImmunotherapyPatientsOncologistsDiagnosisCareA 3D quantitative imaging biomarker in pre-treatment MRI predicts overall survival after stereotactic radiation therapy of patients with a singular brain metastasis
Della Seta M, Collettini F, Chapiro J, Angelidis A, Engeling F, Hamm B, Kaul D. A 3D quantitative imaging biomarker in pre-treatment MRI predicts overall survival after stereotactic radiation therapy of patients with a singular brain metastasis. Acta Radiologica 2019, 60: 1496-1503. PMID: 30841703, DOI: 10.1177/0284185119831692.Peer-Reviewed Original ResearchConceptsIntracranial progression-free survivalSingular brain metastasisStereotactic radiation therapyPre-treatment magnetic resonance imagingMagnetic resonance imagingBrain metastasesPrognostic factorsTumor volumeRadiation therapyCranial magnetic resonance imagingContrast-enhanced MRI scansMultivariable Cox regressionProgression-free survivalIntracranial malignant tumorPrediction of survivalOverall survivalMultivariable analysisPrognostic indexCox regressionRetrospective studyMalignant tumorsQuantitative imaging biomarkersMRI scansPatientsRadiomic biomarkers
2018
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma.
Abajian A, Murali N, Savic LJ, Laage-Gaupp FM, Nezami N, Duncan JS, Schlachter T, Lin M, Geschwind JF, Chapiro J. Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma. Journal Of Visualized Experiments 2018 PMID: 30371657, PMCID: PMC6235502, DOI: 10.3791/58382.Peer-Reviewed Original ResearchConceptsIntra-arterial therapyN patientsHepatocellular carcinomaTrans-arterial therapiesIntra-arterial treatmentCohort of patientsStandard of careLikelihood of responseClinical research questionsSurgical resectionNew patientsTreatment responseUnivariate associationsPatientsTraining patientsInterventional radiologyTherapyCarcinomaTreatmentImage-guided therapyOutcomesFinal modelImaging dataResectionResponsePredicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning—An Artificial Intelligence Concept
Abajian A, Murali N, Savic LJ, Laage-Gaupp FM, Nezami N, Duncan JS, Schlachter T, Lin M, Geschwind JF, Chapiro J. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning—An Artificial Intelligence Concept. Journal Of Vascular And Interventional Radiology 2018, 29: 850-857.e1. PMID: 29548875, PMCID: PMC5970021, DOI: 10.1016/j.jvir.2018.01.769.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticContrast MediaDoxorubicinEthiodized OilFemaleHumansLiver NeoplasmsMachine LearningMagnetic Resonance ImagingMaleMiddle AgedNeoplasm StagingPredictive Value of TestsRetrospective StudiesSensitivity and SpecificityTreatment OutcomeConceptsTransarterial chemoembolizationHepatocellular carcinomaTreatment responseLogistic regressionClinical patient dataPatient dataIntra-arterial therapyQuantitative European AssociationMagnetic resonance imagingLiver criteriaBaseline imagingClinical variablesTumor responseTherapeutic featuresTreatment respondersBaseline MRClinical informationImaging variablesChemoembolizationTherapeutic outcomesResonance imagingResponse criteriaEuropean AssociationPatientsMR imagingClinical Experience with Real-Time 3-D Guidance Based on C-Arm-Acquired Cone-Beam CT (CBCT) in Transjugular Intrahepatic Portosystemic Stent Shunt (TIPSS) Placement
Böning G, Lüdemann WM, Chapiro J, Jonczyk M, Hamm B, Günther RW, Gebauer B, Streitparth F. Clinical Experience with Real-Time 3-D Guidance Based on C-Arm-Acquired Cone-Beam CT (CBCT) in Transjugular Intrahepatic Portosystemic Stent Shunt (TIPSS) Placement. CardioVascular And Interventional Radiology 2018, 41: 1035-1042. PMID: 29541837, DOI: 10.1007/s00270-018-1877-4.Peer-Reviewed Original ResearchMeSH KeywordsCone-Beam Computed TomographyFeasibility StudiesFemaleFluoroscopyHepatic VeinsHumansHypertension, PortalImaging, Three-DimensionalMaleMiddle AgedPortal VeinPortasystemic Shunt, Transjugular IntrahepaticProspective StudiesPuncturesRadiography, InterventionalRetrospective StudiesStentsTreatment OutcomeUltrasonographyConceptsPuncture attemptsTIPSS placementTIPSS procedureProcedure timeTransjugular intrahepatic portosystemic stent shunt placementMean puncture timeSuccess ratePortal vein punctureSignificant differencesShunt placementPuncture timeConsecutive casesMedian numberProspective groupVein punctureUS guidanceClinical experienceControl groupCone beamStudy designCone-beam CTMean timeDoseCBCT guidancePatients
2017
Diagnostic Accuracy of Split-Bolus Single-Phase Contrast-Enhanced Cone-Beam CT for the Detection of Liver Tumors before Transarterial Chemoembolization
Jonczyk M, Chapiro J, Collettini F, Geisel D, Schnapauff D, Streitparth F, Schmidt T, Hamm B, Gebauer B, Wieners G. Diagnostic Accuracy of Split-Bolus Single-Phase Contrast-Enhanced Cone-Beam CT for the Detection of Liver Tumors before Transarterial Chemoembolization. Journal Of Vascular And Interventional Radiology 2017, 28: 1378-1385. PMID: 28747271, DOI: 10.1016/j.jvir.2017.05.018.Peer-Reviewed Original ResearchConceptsTransarterial chemoembolizationHepatocellular carcinomaMR imagingCone-beam CTContrast injectionSingle-center studyContrast-enhanced MR imagingHypervascularized tumorsMore tumorsLiver tumorsHCC tumorsPhase MR imagingHepatobiliary phase MRIntraindividual comparisonTumorsChemoembolizationDiagnostic accuracyCTArterial phase MR imagingStatistical differenceWilcoxon testIndependent readersCone-beam CT imagesPatientsBetter tumor detectionThe impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma
Smolka S, Chapiro J, Manzano W, Treilhard J, Reiner E, Deng Y, Zhao Y, Hamm B, Duncan JS, Gebauer B, Lin M, Geschwind JF. The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma. Clinical Imaging 2017, 46: 1-7. PMID: 28668723, PMCID: PMC5720941, DOI: 10.1016/j.clinimag.2017.05.007.Peer-Reviewed Original ResearchConceptsEarly response assessmentTransarterial chemoembolizationImaging-based criteriaResponse assessmentHepatocellular carcinomaTumor response assessmentAnti-angiogenic therapyQuantitative European AssociationTherapy armOverall survivalLiver criteriaAntiangiogenic therapyTreatment groupsPatientsSimilar associationEuropean AssociationBevacizumabChemoembolizationCarcinomaTherapyAssociationAssessmentFollowCriteriaBaseline
2016
Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?
Sahu S, Schernthaner R, Ardon R, Chapiro J, Zhao Y, Sohn JH, Fleckenstein F, Lin M, Geschwind JF, Duran R. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival? Radiology 2016, 283: 160838. PMID: 27831830, PMCID: PMC5425309, DOI: 10.1148/radiol.2016160838.Peer-Reviewed Original ResearchConceptsNeuroendocrine liver metastasesWorld Health OrganizationContrast material-enhanced magnetic resonance (MR) imagesFirst TACE procedureResponse Evaluation CriteriaKaplan-Meier curvesTreatment response biomarkersTransarterial chemoembolization proceduresInstitutional review boardFirst TACELiver methodLiver metastasesIndependent predictorsTumor burdenRetrospective studyTACE proceduresCox regressionOnly biomarkerSurvival differencesChemoembolization proceduresTreatment responseResponse biomarkersPatientsSolid tumorsNormal liver3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival
Fleckenstein FN, Schernthaner RE, Duran R, Sohn JH, Sahu S, Zhao Y, Hamm B, Gebauer B, Lin M, Geschwind JF, Chapiro J. 3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival. European Radiology 2016, 26: 3243-3252. PMID: 26762942, PMCID: PMC4942412, DOI: 10.1007/s00330-015-4168-3.Peer-Reviewed Original ResearchConceptsHazard ratioOverall survivalTransarterial chemoembolizationBaseline MRIHepatocellular carcinomaTumor burdenDominant lesionTumor assessmentTumor volumeMultivariate cox proportional hazard ratiosCox proportional hazard ratiosCurrent radiological methodMethodsThis retrospective analysisProportional hazard ratiosBCLC staging systemKaplan-Meier plotsTumor diameterPatient survivalStaging systemHCC patientsMultiple lesionsLiver volumeRetrospective analysisLesion assessmentPatients
2015
3D quantitative assessment of response to fractionated stereotactic radiotherapy and single-session stereotactic radiosurgery of vestibular schwannoma
Schneider T, Chapiro J, Lin M, Geschwind JF, Kleinberg L, Rigamonti D, Jusué-Torres I, Marciscano AE, Yousem DM. 3D quantitative assessment of response to fractionated stereotactic radiotherapy and single-session stereotactic radiosurgery of vestibular schwannoma. European Radiology 2015, 26: 849-857. PMID: 26139318, PMCID: PMC4698362, DOI: 10.1007/s00330-015-3895-9.Peer-Reviewed Original ResearchConceptsSingle-session stereotactic radiosurgeryTotal tumor volumeSignificant tumor shrinkageVestibular schwannomaTumor shrinkageStereotactic radiotherapyTumor volumeRadiation therapyStereotactic radiosurgeryT1-weighted contrast-enhanced MRISubsequent microsurgical resectionTumor-related symptomsSporadic vestibular schwannomaContrast-enhanced MRIFSRT groupRadiological progressionMicrosurgical resectionClinical outcomesSRS groupRetrospective analysisResponse assessmentPatientsVolumetric assessmentFSRTSchwannoma